Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).

abstract：:One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

journal_title：Hematological oncology

authors： Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

更新日期：1993-01-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...

journal_title：Hematological oncology

authors： Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov A

更新日期：2017-06-01 00:00:00

abstract：:There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

journal_title：Hematological oncology

authors： Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

更新日期：2019-08-01 00:00:00

abstract：:Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...

journal_title：Hematological oncology

authors： Thompson CA,Yost KJ,Maurer MJ,Allmer C,Farooq U,Habermann TM,Inwards DJ,Macon WR,Link BK,Rosenthal AC,Cerhan JR

更新日期：2018-12-01 00:00:00

abstract：:The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...

journal_title：Hematological oncology

authors： Maruo N,Horiuchi H,Nakabo T,Kondo M,Nakamura T

更新日期：1985-01-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a du...

journal_title：Hematological oncology

authors： Baumann M,Cerny T,Sommacal A,Koeberle D

更新日期：2012-06-01 00:00:00

abstract：:Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...

journal_title：Hematological oncology

authors： Kanda Y,Kami M,Matsuyama T,Mitani K,Chiba S,Yazaki Y,Hirai H

更新日期：1998-03-01 00:00:00

abstract：:The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...

journal_title：Hematological oncology

authors： Fozza C

更新日期：2018-02-01 00:00:00

abstract：:Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...

journal_title：Hematological oncology

authors： Smith GM,Wright D,Child JA,Simmons AV,Norfolk DR,Barnard DL,Parker D,Parapia L

更新日期：1992-11-01 00:00:00

abstract：:We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

journal_title：Hematological oncology

authors： Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

更新日期：1994-05-01 00:00:00

abstract：:The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

journal_title：Hematological oncology

authors： Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

更新日期：2019-10-01 00:00:00

abstract：:From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...

journal_title：Hematological oncology

authors： Chim CS,Kwong YL,Lie AK,Lee CK,Liang R

更新日期：1998-09-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

journal_title：Hematological oncology

authors： Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

更新日期：2012-09-01 00:00:00

abstract：:Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...

journal_title：Hematological oncology

authors： Hast R,Axdorph S,Laurén L,Reizenstein P

更新日期：1989-07-01 00:00:00

abstract：:The glucose-6-phosphatase (G-6-Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G-6-Pase cytochemical profile on lymph node imprint prep...

journal_title：Hematological oncology

authors： Pangalis GA,Tsavaris NB

更新日期：1986-10-01 00:00:00

abstract：:Bone marrow (BM) is accepted as the tissue of choice for the detection of monoclonal populations in leukemias and lymphomas; however, obtaining BM can be painful and traumatic for the patients. Although it is possible to detect clonality in peripheral blood (PB) samples, there are no reports comparing the results obse...

journal_title：Hematological oncology

authors： Leal E,Esparza-Flores MA,López-Guido B,Aguilar-Luna C,Aguilar-López L,Jaloma-Cruz AR,Medina C,Barros-Núñez P

更新日期：2003-03-01 00:00:00

abstract：:The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and J...

journal_title：Hematological oncology

authors： Santoro M,Accurso V,Mancuso S,Carlisi M,Raso S,Tarantino G,Di Piazza F,Perez A,Russo A,Siragusa S

更新日期：2019-10-01 00:00:00

abstract：:Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

journal_title：Hematological oncology

authors： Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

更新日期：2017-09-01 00:00:00

abstract：:To clarify the origin of Hodgkin (H) and Sternberg-Reed (SR) cells, frozen sections of lymph nodes from 30 patients with Hodgkin's disease were immunostained with a large panel of monoclonal antibodies reactive with cells of lymphoid tissue and granulopoiesis. The results showed that: (a) H and SR cells are devoid of ...

journal_title：Hematological oncology

authors： Stein H,Gerdes J,Schwab U,Lemke H,Diehl V,Mason DY,Bartels H,Ziegler A

更新日期：1983-01-01 00:00:00

abstract：:This paper presents a new analysis of aspects of the descriptive epidemiology of multiple myeloma (MM) for parts of the U.K., 1984-1993. It provides no indication for geographical heterogeneity, nor is there evidence of a decline in rates over the decade. There is, however, evidence that cancer registration inflates M...

journal_title：Hematological oncology

authors： Cartwright RA,Gilman EA,Nicholson P,Allon D

更新日期：1999-03-01 00:00:00

abstract：:Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...

journal_title：Hematological oncology

authors： Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz F

更新日期：2016-12-01 00:00:00

abstract：:Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...

journal_title：Hematological oncology

authors： Miura K,Tsujimura H,Masaki Y,Iino M,Takizawa J,Maeda Y,Yamamoto K,Tamura S,Yoshida A,Yagi H,Yoshida I,Kitazume K,Masunari T,Choi I,Kakinoki Y,Suzuki R,Yoshino T,Nakamura S,Hatta Y,Yoshida T,Kanno M

更新日期：2020-09-25 00:00:00

abstract：:The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

journal_title：Hematological oncology

authors： Cotter FE

更新日期：1997-02-01 00:00:00

abstract：:There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA brea...

journal_title：Hematological oncology

authors： Golla RM,Li M,Shen Y,Ji M,Yan Y,Fu K,Greiner TC,McKeithan TW,Chan WC

更新日期：2012-12-01 00:00:00

abstract：:Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

journal_title：Hematological oncology

authors： Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

更新日期：2020-10-01 00:00:00

abstract：:Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...

journal_title：Hematological oncology

authors： Nwangwu CA,Weiher H,Schmidt-Wolf IGH

更新日期：2017-12-01 00:00:00

abstract：:Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...

journal_title：Hematological oncology

authors： Mughal MK,Akhter A,Street L,Pournazari P,Shabani-Rad MT,Mansoor A

更新日期：2017-09-01 00:00:00

abstract：:A new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T-cell chronic lymphocytic leukemia (T-CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patients' cells and leukemia-lymphoma cell lines. The results demonstrated that thi...

journal_title：Hematological oncology

authors： Togashi H,Ghoneum M,Takasugi M,Kasai K,Mugishima H,Billing R,Terasaki PI

更新日期：1989-05-01 00:00:00

abstract：:Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

journal_title：Hematological oncology

authors： Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

更新日期：2015-12-01 00:00:00

abstract：:The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

journal_title：Hematological oncology

authors： Chetty R,Bickhoo A

更新日期：1997-11-01 00:00:00